BioSpace Collaborative

Academic/Biomedical Research
News & Jobs
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  C2C Services & Suppliers™
Europe
Asia

DIVERSITY

PROFILES
Company Profiles

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Research Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
Get Our Industry eNewsletter FREE email:    
   

San Diego State University Study Shows Antibody May Reduce Or Eliminate Tumors


3/13/2006 1:02:44 PM

SAN DIEGO, March 13 /PRNewswire/ -- San Diego State University researcher Roger Sabbadini has brought scientists one step closer to finding a cure for cancer with the creation of an antibody that hinders the growth of tumors by preventing blood vessel formation.

As published in the March 14 issue of Cancer Cell, a leading oncology journal, Sabbadini and his research team have created an antibody, Sphingomab(TM), that can be used as a drug to reduce the size of tumors in experimental animal models of human cancer. The antibody works as a molecular sponge by soaking up sphingosine-1-phosphate (S1P), a molecule that has been proven to stimulate the growth of new blood vessels. S1P has been identified as a mediator of tumor cell proliferation and protector of tumor cells from chemotherapy drugs. By neutralizing S1P, the Sphingomab antibody inhibits the new blood vessel formation that tumors require to thrive, a process called 'tumor angiogenesis.'

The group's research tested the antibody in mice tissue implanted with drug-resistant human breast, ovarian and lung cancer cell lines, as well as a mouse skin cancer cell line. In ovarian cancer models, two of five subjects displayed no tumors, and three subjects had tumors with 68 percent less volume than those in the control group. Tumors were reduced by about 60 percent in volume in lung and breast cancer models.

"This groundbreaking research provides new hope for therapeutic treatments for forms of cancer that are resistant to current therapeutics," Sabbadini said. "The Sphingomab antibody is especially powerful as it is shown to prevent tumors from a variety of cancers, as opposed to being effective against only one type of cancer."

Sabbadini's previous sphingolipid research led to the founding of Lpath Inc.

"It has become a dream of mine to be a part of great anti-cancer research, as my mother is a cancer survivor," said Bradley Sibbald, a master's degree candidate in SDSU's molecular biology program and a co-author of the study. "With the creation of this antibody, I now have a new investigative tool to help cure cancers with liquid tumors, which is the focus of my current research."

The research team was primarily comprised of current and former students of SDSU, as well as researchers affiliated with Lpath Inc. Besides Sibbald, other authors of the study include Barbara Visentin, John Vekich, Amy Cavalli and Kelli Moreno, all former SDSU students. Other contributing researchers include Rosalia Matteo and William Garland, both with Lpath Inc., and University of Texas Anderson Cancer Center researchers Shuangxing Yu, Yiling Lu, Hassan Hall, Vikas Kundra and Gordon Mills.

Sabbadini will present the team's findings at the annual conference for the American Association of Cancer Researchers, April 1 - 5, in Washington D.C. Additionally, Lpath Inc. is preparing an application to the U.S. Food and Drug Administration for approval to use the antibody for human clinical trials.

Lpath is a theranostics company focused on bioactive signaling lipids as targets for treating and diagnosing important human diseases. For more information on Lpath, visit www.lpath.com.

SDSU is the oldest and largest institution of higher education in the San Diego region. Founded in 1897, SDSU offers bachelor's degrees in 81 areas, master's degrees in 72 and doctorates in 16. SDSU's more than 33,000 students participate in academic curricula distinguished by direct faculty contact and an increasingly international emphasis that prepares them for a global future. For more information, visit www.sdsu.edu.

Contact: Lorena Nava San Diego State University (619) 594-3952 office; (619) 309-5179 cell lnava@mail.sdsu.edu

Diego State University; Lpath Inc.

San

CONTACT: Lorena Nava of San Diego State University, +1-619-594-3952, orcell, +1-619-309-5179, lnava@mail.sdsu.edu


Read at BioSpace.com

CSUPERB
 
 

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES
 

//-->